Guggenheim lowered the firm’s price target on GeneDx (WGS) to $70 from $100 and keeps a Buy rating on the shares. This “was a tough update, especially given that guidance was provided with 5 weeks left in Q1 and the tone at major conferences was fine,” but valuation and the outlook keep the firm on board, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- GeneDx price target lowered to $75 from $100 at Canaccord
- GeneDx price target lowered to $75 from $155 at Wells Fargo
- Genedx Earnings Call Resets Outlook Amid Strong Growth
- Closing Bell Movers: Pinterest jumps 15% on earnings beat; Palantir slips
- GeneDx reports Q1 adjusted loss ($8.2M) vs. ($9.2M) last year